Nutra Pharma Announces Granted Continuing Education for Pharmacists
Nutra Pharma announces providing an educational grant for the Pharmacist Continuing Education course "Over-the-Counter Use of Neuroactive Peptides for the Treatment of Chronic Pain"
January 20, 2010 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has provided an educational grant for the Pharmacist Continuing Education course "Over-the-Counter Use of Neuroactive Peptides for the Treatment of Chronic Pain". This course was sponsored by Postgraduate Healthcare Education, LLC (PHE) and is already available on the Power-Pak website (www.powerpak.com).
“We are pleased to provide this educational grant so that Pharmacists can be better educated on the options available to patients with chronic pain,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We believe that these sort of educational activities are the key to providing a better foundation for the treatment of chronic pain and inflammation,” he concluded.
The goal of the course is to provide an overview of neuroactive peptides and their medical applications, with specific emphasis on patients with pain syndromes. After completing the course, participants should be able to:
· Review the historical use of snake venom for the treatment of medical conditions, particularly those requiring pain relief;
· Discuss the scientific basis for the use of neuroactive peptides from snake venom for treating physical conditions, such as chronic and acute pain;
· Describe the available pain medications that operate according to these mechanisms and review their safety and efficacy data;
· Develop patient education strategies about the use of snake venom-based medications for pain relief, particularly over- the-counter preparations.
The CE lesson is available at the Power-Pak website as well as through US Pharmacist. The activity provides 2 credit hours to Pharmacists that complete the course.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Providing RPI-78M under compassionate release to patients enrolled in the Adrenomyeloneuropathy (AMN) clinical study should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.